SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
University of Washington
University of Washington
Fred Hutchinson Cancer Center
Mayo Clinic
Roswell Park Cancer Institute
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Roswell Park Cancer Institute
Mayo Clinic
Emory University
University of Washington
NRG Oncology
NRG Oncology
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
University of Washington
City of Hope Medical Center
University of Washington
Northwestern University
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
NRG Oncology
City of Hope Medical Center
City of Hope Medical Center
University of Utah
Vanderbilt-Ingram Cancer Center
Roswell Park Cancer Institute
University of Washington
Albert Einstein College of Medicine
Emory University
University of Washington
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
University of Washington
Wake Forest University Health Sciences
Centre Henri Becquerel
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Ontario Clinical Oncology Group (OCOG)
Stanford University
Abramson Cancer Center at Penn Medicine
City of Hope Medical Center
Radboud University Medical Center